CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

NCT04893486 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

BCCs in Gorlin Syndrome Patients

Interventions

DRUG: PTX-022
DRUG: Vehicle comparator

Sponsor

Palvella Therapeutics, Inc.